These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 23804423)

  • 1. Acquired resistance to anti-VEGF therapy in glioblastoma is associated with a mesenchymal transition.
    Piao Y; Liang J; Holmes L; Henry V; Sulman E; de Groot JF
    Clin Cancer Res; 2013 Aug; 19(16):4392-403. PubMed ID: 23804423
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glioblastoma resistance to anti-VEGF therapy is associated with myeloid cell infiltration, stem cell accumulation, and a mesenchymal phenotype.
    Piao Y; Liang J; Holmes L; Zurita AJ; Henry V; Heymach JV; de Groot JF
    Neuro Oncol; 2012 Nov; 14(11):1379-92. PubMed ID: 22965162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis.
    Bota DA; Alexandru D; Keir ST; Bigner D; Vredenburgh J; Friedman HS
    J Neurosurg; 2013 Dec; 119(6):1415-23. PubMed ID: 24093630
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clonal ZEB1-Driven Mesenchymal Transition Promotes Targetable Oncologic Antiangiogenic Therapy Resistance.
    Chandra A; Jahangiri A; Chen W; Nguyen AT; Yagnik G; Pereira MP; Jain S; Garcia JH; Shah SS; Wadhwa H; Joshi RS; Weiss J; Wolf KJ; Lin JG; Müller S; Rick JW; Diaz AA; Gilbert LA; Kumar S; Aghi MK
    Cancer Res; 2020 Apr; 80(7):1498-1511. PubMed ID: 32041837
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene expression profile identifies tyrosine kinase c-Met as a targetable mediator of antiangiogenic therapy resistance.
    Jahangiri A; De Lay M; Miller LM; Carbonell WS; Hu YL; Lu K; Tom MW; Paquette J; Tokuyasu TA; Tsao S; Marshall R; Perry A; Bjorgan KM; Chaumeil MM; Ronen SM; Bergers G; Aghi MK
    Clin Cancer Res; 2013 Apr; 19(7):1773-83. PubMed ID: 23307858
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neutrophils promote the malignant glioma phenotype through S100A4.
    Liang J; Piao Y; Holmes L; Fuller GN; Henry V; Tiao N; de Groot JF
    Clin Cancer Res; 2014 Jan; 20(1):187-98. PubMed ID: 24240114
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy.
    Lucio-Eterovic AK; Piao Y; de Groot JF
    Clin Cancer Res; 2009 Jul; 15(14):4589-99. PubMed ID: 19567589
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Macrophage migration inhibitory factor downregulation: a novel mechanism of resistance to anti-angiogenic therapy.
    Castro BA; Flanigan P; Jahangiri A; Hoffman D; Chen W; Kuang R; De Lay M; Yagnik G; Wagner JR; Mascharak S; Sidorov M; Shrivastav S; Kohanbash G; Okada H; Aghi MK
    Oncogene; 2017 Jun; 36(26):3749-3759. PubMed ID: 28218903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-VEGF treatment-resistant pancreatic cancers secrete proinflammatory factors that contribute to malignant progression by inducing an EMT cell phenotype.
    Carbone C; Moccia T; Zhu C; Paradiso G; Budillon A; Chiao PJ; Abbruzzese JL; Melisi D
    Clin Cancer Res; 2011 Sep; 17(17):5822-32. PubMed ID: 21737511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined inhibition of IL1, CXCR1/2, and TGFβ signaling pathways modulates in-vivo resistance to anti-VEGF treatment.
    Carbone C; Tamburrino A; Piro G; Boschi F; Cataldo I; Zanotto M; Mina MM; Zanini S; Sbarbati A; Scarpa A; Tortora G; Melisi D
    Anticancer Drugs; 2016 Jan; 27(1):29-40. PubMed ID: 26473526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Microarray analysis verifies two distinct phenotypes of glioblastomas resistant to antiangiogenic therapy.
    DeLay M; Jahangiri A; Carbonell WS; Hu YL; Tsao S; Tom MW; Paquette J; Tokuyasu TA; Aghi MK
    Clin Cancer Res; 2012 May; 18(10):2930-42. PubMed ID: 22472177
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel MET/TIE2/VEGFR2 inhibitor altiratinib inhibits tumor growth and invasiveness in bevacizumab-resistant glioblastoma mouse models.
    Piao Y; Park SY; Henry V; Smith BD; Tiao N; Flynn DL; de Groot JF
    Neuro Oncol; 2016 Sep; 18(9):1230-41. PubMed ID: 26965451
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD44 expression in the tumor periphery predicts the responsiveness to bevacizumab in the treatment of recurrent glioblastoma.
    Nishikawa M; Inoue A; Ohnishi T; Yano H; Kanemura Y; Kohno S; Ohue S; Ozaki S; Matsumoto S; Suehiro S; Nakamura Y; Shigekawa S; Watanabe H; Kitazawa R; Tanaka J; Kunieda T
    Cancer Med; 2021 Mar; 10(6):2013-2025. PubMed ID: 33543833
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Direct effect of bevacizumab on glioblastoma cell lines in vitro.
    Simon T; Coquerel B; Petit A; Kassim Y; Demange E; Le Cerf D; Perrot V; Vannier JP
    Neuromolecular Med; 2014 Dec; 16(4):752-71. PubMed ID: 25113866
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DLL4-Notch signaling mediates tumor resistance to anti-VEGF therapy in vivo.
    Li JL; Sainson RC; Oon CE; Turley H; Leek R; Sheldon H; Bridges E; Shi W; Snell C; Bowden ET; Wu H; Chowdhury PS; Russell AJ; Montgomery CP; Poulsom R; Harris AL
    Cancer Res; 2011 Sep; 71(18):6073-83. PubMed ID: 21803743
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor-resistant human lung adenocarcinoma.
    Cascone T; Herynk MH; Xu L; Du Z; Kadara H; Nilsson MB; Oborn CJ; Park YY; Erez B; Jacoby JJ; Lee JS; Lin HY; Ciardiello F; Herbst RS; Langley RR; Heymach JV
    J Clin Invest; 2011 Apr; 121(4):1313-28. PubMed ID: 21436589
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SDF-1 Blockade Enhances Anti-VEGF Therapy of Glioblastoma and Can Be Monitored by MRI.
    Deng L; Stafford JH; Liu SC; Chernikova SB; Merchant M; Recht L; Martin Brown J
    Neoplasia; 2017 Jan; 19(1):1-7. PubMed ID: 27940247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A proangiogenic signature is revealed in FGF-mediated bevacizumab-resistant head and neck squamous cell carcinoma.
    Gyanchandani R; Ortega Alves MV; Myers JN; Kim S
    Mol Cancer Res; 2013 Dec; 11(12):1585-96. PubMed ID: 24092775
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glioblastoma endothelium drives bevacizumab-induced infiltrative growth via modulation of PLXDC1.
    Falchetti ML; D'Alessandris QG; Pacioni S; Buccarelli M; Morgante L; Giannetti S; Lulli V; Martini M; Larocca LM; Vakana E; Stancato L; Ricci-Vitiani L; Pallini R
    Int J Cancer; 2019 Mar; 144(6):1331-1344. PubMed ID: 30414187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypoxia suppresses cylindromatosis (CYLD) expression to promote inflammation in glioblastoma: possible link to acquired resistance to anti-VEGF therapy.
    Guo J; Shinriki S; Su Y; Nakamura T; Hayashi M; Tsuda Y; Murakami Y; Tasaki M; Hide T; Takezaki T; Kuratsu J; Yamashita S; Ueda M; Li JD; Ando Y; Jono H
    Oncotarget; 2014 Aug; 5(15):6353-64. PubMed ID: 25071012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.